Lundbeck’s New Partners: Research With Genmab, Marketing With Merck
Executive Summary
Lundbeck has entered into a research collaboration with fellow Danish company Genmab, its first since announcing a new R&D strategy in September. It’s the second collaboration for Genmab since that company also updated its corporate strategy at around the same time.
You may also be interested in...
Lundbeck Breaks Into MAb Development, Adds To Suite Of Parkinson's Candidates
Denmark's mid-sized biopharma, Lundbeck, has taken another potential Parkinson's disease therapeutic into early clinical studies, the third this year, and this time it's a monoclonal antibody, not a small molecule.
Lundbeck Leans On Licensing To Overcome Lexapro/Cipralex Expiry
As lead drug Lexapro/Cipralex faces genericization, Lundbeck is counting on revenues from ongoing licensing deals to fill the $1 billion hole.
Lundbeck Leans On Licensing To Overcome Lexapro/Cipralex Expiry
As lead drug Lexapro/Cipralex faces genericization, Lundbeck is counting on revenues from ongoing licensing deals to fill the $1 billion hole.